Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vemurafenib, Irinotecan, and Cetuximab in BRAF V600E-Mutant Metastatic Colorectal Cancer
NCT04790448Phase 2Completed
- Sponsor
- Sun Yat-sen University
- Start
- Jul 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vemurafenib in colorectal cancer (metastatic) (mCRC), sponsored by Sun Yat-sen University. Started Jul 2020; status: completed.
02
Drugs
vemurafenib
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT04790448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04790448.